Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXB-241 Vaccine Candidate in Older Adults With Run-in in Young Adults
NCT06556147Phase 1Active, not recruiting
- Sponsor
- Sanofi
- Start
- Aug 2024
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of RSV/hMPV vaccine in respiratory syncytial virus infection (RSV) and human metapneumovirus infection (HMPV) (14 arms), sponsored by Sanofi. Primary endpoints: Proportion of Older Adult Participants With 1 or More Unsolicited AEs at 1 month, Proportion of Older Adult Participants With 1 or More Solicited AEs at 7 days and 2 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
RSV/hMPV vaccine
03
Conditions
respiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on NCT06556147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556147.